**SUPPLEMENTARY DATA**

**Supplementary Table 1: Number of Patients by Country and LAI Use**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Austria** | **France** | **Germany** | **Spain** | **Sweden** | **UK** | **Overall** |
| Patients, n (%) | 7 (1.2) | 146 (25.5) | 164 (28.7) | 89 (15.6) | 12 (2.1) | 154 (26.9) | 572 (100.0) |
| Incident FGA-LAI Users, n (%) | 3 (42.9) | 17 (11.6) | 5 (3.0) | 8 (9.0) | 0 (0.0) | 18 (11.7) | 51 (8.9) |
| Incident SGA-LAI User, n (%) | 4 (57.1) | 63 (43.2) | 47 (28.7) | 43 (48.3) | 0 (0.0) | 33 (21.4) | 190 (33.2) |
| Prevalent FGA-LAI Users, n (%) | 0 (0.0) | 32 (21.9) | 57 (34.8) | 27 (30.3) | 8 (66.7) | 85 (55.2) | 209 (36.5) |
| Prevalent SGA-LAI Users, n (%) | 0 (0.0) | 34 (23.3) | 55 (33.5) | 11 (12.4) | 4 (33.3) | 18 (11.7) | 122 (21.3) |

FGA: first generation antipsychotic, LAI: long-acting injectable, SGA: second generation antipsychotic.

**Supplementary Table 2: Physician-Rated Non-Adherence Risk by LAI User Type**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Risk Factor, n (%)** | **Prevalent FGA-LAI (n=209)** | **Prevalent SGA-LAI (n=122)** | **Incident FGA-LAI (n=51)** | **Incident SGA-LAI (n=190)** | **Overall (N=572)** |
| Prior violent behavior | 48 (23.0) | 7 (5.7) | 13 (25.5) | 22 (11.6) | 90 (15.7) |
| Documented history of medication non-adherence | 73 (34.9) | 43 (35.2) | 25 (49.0) | 70 (36.8) | 211 (36.9) |
| Inadequate response to primary AP treatment | 27 (12.9) | 16 (13.1) | 11 (21.6) | 21 (11.1) | 75 (13.1) |
| Alcohol abuse | 33 (15.8) | 1 (0.8) | 10 (19.6) | 21 (11.1) | 65 (11.4) |
| Drug abuse | 34 (16.3) | 9 (7.4) | 15 (29.4) | 23 (12.1) | 81 (14.2) |
| Other | 2 (1.0) | 1 (0.8) | 0 (0.0) | 2 (1.1) | 5 (0.9) |
|  | | | | | |
| **None** | 90 (43.1) | 57 (46.7) | 9 (17.6) | 79 (41.6) | 235 (41.1) |
| **At Risk** | 119 (56.9) | 65 (53.3) | 42 (82.4) | 111 (58.4) | 337 (58.9) |

AP: Antipsychotic, FGA-LAI: first generation antipsychotic long-acting injectable, SGA-LAI, second generation antipsychotic long-acting injectable.

**Supplementary Table 3: Patient Subgroups by Country**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Subgroupa, n (%)** | **Austria**  **(n=7)** | **France**  **(n=146)** | **Germany**  **(n=164)** | **Spain**  **(n=89)** | **Sweden**  **(n=12)** | **UK**  **(n=154)** | **Overall**  **(N=572)** |
| LAI naïve users | 4 (57.1) | 88 (60.3) | 104 (63.4) | 44 (49.4) | 7 (58.3) | 74 (48.1) | 321 (56.1) |
| Treatment resistant patientsb | 1 (14.3) | 9 (6.2) | 18 (11.0) | 6 (6.7) | 2 (16.7) | 16 (10.4) | 52 (9.1) |
| Mainly untreated patientsc | 4 (57.1) | 91 (62.3) | 142 (86.6) | 58 (65.2) | 12 (100.0) | 124 (80.5) | 431 (75.3) |
| Mainly previously treated by Orald | 2 (28.6) | 33 (22.6) | 17 (10.4) | 14 (15.7) | 0 (0.0) | 20 (13.0) | 86 (15.0) |
| Mainly previously treated by LAIe | 1 (14.3) | 22 (15.1) | 5 (3.0) | 17 (19.1) | 0 (0.0) | 10 (6.5) | 55 (9.6) |
| Socially withdrawnf | 6 (85.7) | 118 (80.8) | 133 (81.1) | 57 (64.0) | 11 (91.7) | 131 (85.1) | 456 (79.7) |
| Aggressive disorderg | 0 (0.0) | 11 (7.5) | 14 (8.5) | 15 (16.9) | 0 (0.0) | 34 (22.1) | 74 (12.9) |
| Depressive disorderh | 5 (71.4) | 69 (47.3) | 96 (58.5) | 29 (32.6) | 7 (58.3) | 98 (63.6) | 304 (53.1) |
| Anxiety disorderi | 5 (71.4) | 82 (56.2) | 52 (31.7) | 47 (52.8) | 6 (50.0) | 76 (49.4) | 268 (46.9) |
| Early in diseasej | 5 (71.4) | 64 (43.8) | 44 (26.8) | 30 (33.7) | 4 (33.3) | 66 (42.9) | 213 (37.2) |
| High functioning and youngk | 0 (0.0) | 18 (12.3) | 17 (10.4) | 5 (5.6) | 2 (16.7) | 14 (9.1) | 56 (9.8) |
| Low functioning and chronicl | 0 (0.0) | 8 (5.5) | 5 (3.0) | 16 (18.0) | 1 (8.3) | 10 (6.5) | 40 (7.0) |

LAI: long-acting injectable. aSubgroups of patients (clusters of antipsychotic LAI users) were identified according to the specific sets of attributes listed as follows: bPatient previously received clozapine medicine. cPatient whose treatment duration is ≤6 months. dPatient treated >50% of the year and receiving oral treatment for >50% of overall treatment duration. ePatient treated >50% of the year and receiving LAI for >50% of overall treatment duration. fPatient with living status ‘homeless’ or ‘living alone’, and/or caregiver status as ‘absence of caregiver’, or employment status as ‘unemployed’ and marital status is ‘single’, ‘divorced/separated’ or ‘widow’ and/or items a or b of the Personal and Social Performance (PSP) scale is ‘very severe’. gPatient with PSP scale domain “Disturbing and aggressive behaviors” ‘manifest’, ‘marked’, ‘severe’, or ‘very severe’. hPatient with depressive disorder or depressive symptoms either in the past or at time of enrollment, or who had ≥1 past suicide attempt, or an ongoing antidepressant prescription documented at time of enrollment. iPatient with past or current Anxiety Disorder at time of enrollment or an anxiolytic prescription is ongoing at time of enrollment. jPatient <35 years old or time since schizophrenia diagnosis <5 years. kPatient (i) ≤35 years old or time since schizophrenia diagnosis <10 years and (ii) G12 PANSS item is absent, minimal or mild, and (iii) GAF >61, and (iv) paid, self-employed, full-time, part-time, voluntary unpaid or student or living area is individual residence. lPatient (i) ≥40 years old or time since schizophrenia diagnosis ≥15 years and (ii) G12 PANSS is moderate severe or severe or extreme, and (iii) GAF is <51, and (iv) is unemployed, has a disability pension, whose living area is homeless, or is institutionalized.

**Supplementary Table 4: Other Current Psychotropic Medications**

|  |  |  |  |
| --- | --- | --- | --- |
| **Other current psychotropic medications** | **Incident FGA-LAI Users (N=51)** | **Incident SGA-LAI Users (N=190)** | **Overall (N=572)** |
| Patients with at least one anti-depressant, n (%) | 15 (29.4) | 39 (20.5) | 126 (22.0) |
| Patients with at least one antiparkinsonians/anticholinergics, n (%) | 20 (39.2) | 24 (12.6) | 130 (22.7) |
| Patients with at least one anxiolytic, n (%) | 22 (43.1) | 69 (36.3) | 148 (25.9) |
| Patients with at least one mood stabilizer/anticonvulsant, n (%) | 6 (11.8) | 21 (11.1) | 55 (9.6) |

FGA: first-generation antipsychotic, LAI: long-acting injectable, SGA: second-generation antipsychotic.

**Supplementary Table 5: Numbers of Patients with Non-Missing UKU Side Effects Rating Scale Responses in Each Side Effect Domain**

|  |  |  |  |
| --- | --- | --- | --- |
| **Domain**  **n (FGA/SGA users)** | **Side Effect (≥10%)** | **Incident FGA-LAI Users**  **among each domain (%)a** | **Incident SGA-LAI Users**  **among each domain (%)a** |
| **Psychic** |  | **N = 213** | **N = 703** |
| Concentration difficulties | 30 (14.1) | 114 (16.2) |
| Increase in asthenia/Lassitude | 30 (14.1) | 101 (14.4) |
| Sleepiness/Sedation | 29 (13.6) | 83 (11.8) |
| Emotional indifference | 26 (12.2) | 76 (10.8) |
| Tension/inner unrest | 24 (11.3) | 73 (10.4) |
| Failing memory | 19 (8.9) | 77 (11.0) |
| **Other** |  | **N = 56** | **N = 221** |
| Diminished sexual drive | 11 (19.6) | 50 (22.6) |
| Orgastic dysfunction | 3 (5.4) | 28 (12.7) |
| Erectile dysfunction | 6 (10.7) | 25 (11.3) |
| Weight gain | 9 (16.1) | 39 (17.6) |
| **Autonomic** |  | **N = 55** | **N = 148** |
| Orthostatic dizziness | 8 (14.5) | 20 (13.5) |
| Accommodation disturbances | 8 (14.5) | 15 (10.1) |
| Increased salivation | 6 (10.9) | 15 (10.1) |
| Reduced salivation | 6 (10.9) | 17 (11.5) |
| Increased tendency to sweating | 7 (12.7) | 15 (10.1) |
| Palpitations/Tachycardia | 6 (10.9) | 15 (10.1) |
| Constipation | 5 (9.1) | 15 (10.1) |
| **Neurologic** |  | **N = 34** | **N = 103** |
| Rigidity | 9 (26.5) | 26 (25.2) |
| Hypokinesia/Akinesia | 6 (17.6) | 26 (25.2) |
| Akathisia | 6 (17.6) | 16 (15.5) |
| Dystonia | 4 (11.8) | 8 (7.8) |
| Tremor | 3 (8.8) | 22 (21.4) |

FGA: first-generation antipsychotic, LAI: long-acting injectable, SGA: second-generation antipsychotic. **a**Percentages among each domain for incident FGA- and SGA-LAI users, respectively, were calculated based on the number of completed assessments for each domain.